ECDB-Endometrial cancer gene database

REFERENCES

Gene Name	Gene ID	Pubmed ID	Classification	Mechanism	Marker	Type	Normal Cases	Disease Cases	Age	Mean Age	Place	FIGO	Grade	Remark	Title	Journal	Volume	Year
BIRC5	332	16826583	-	Up regulation/ Over expression/High expression	-	-	-	17 endometrial adenocarcinoma and 4 atypical endometrium; 60 endometrial adenocarcinoma paraffin-embedded tissue; 20 atypical endometrium paraffin-embedded tissue; 20 normal endometrium paraffin embedded tissue	31 to 77	55	Obstetrics and Gynecology Hospital; Fudan University	I (n=13); II (n=2); III (n=2) [for paraffin- embedded tissue I (n=47); II (n=9); III (n=3); IV (n=1)]	1 (n=12); 2 (n=2); 3 (n=3) [for paraffin- embedded tissue 1 (n=14); 2 (n=13); 3 (n=7)]	[1] Higher levels of survivin mRNA and protein expression were observedin endometrial adenocarcinomas than in atypical or normal endometrium.Immunohistochemical staining revealed that 83.3% (50 of 60) of endometrial adenocarcinomasamples; 55.0% (11 of 20) of atypical endometrium samples; and25.0% (5 of 20) of normal endometrium samples were positive for survivin protein. [2] The MAPK pathway was a signal transduction pathway upstream of survivin.Epidermal growth factor (EGF) and transforming growth factor-a (TGF-a) upregulatedsurvivin protein expression by activating the MAPK pathway in endometrialcancer cells. [3] Survivin promotescell proliferation and cell cycle progression byactivating the cdk4/cyclinD1 complex and enhancing RB phosphorylation to release E2F transcription factor.	Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer.	Cancer	107(4):746-56	2006